Fundraising FoxAgent Capital — 2023 Investments
3 investments dated 2023 · listed companies and verified rows first · show all
Cantai develops rationally designed bispecific antibodies that combine clinically validated mechanisms to treat patients with autoimmune disease.
BiotechHealthtechPhiladelpia, US
Errik Anderson(Executive Officer, Director)inRoss Leimberg(Executive Officer, Director)in
BoardJoshua Brandt(Director)Geeta Vemuri(Executive Officer, Director)in
Co-investors82VS
Jana Care offers a smartphone-enabled at-home blood testing system using its Aina device, paper test strips, and a mobile app to detect key biomarkers for chronic disease management.
Digital HealthHealthtechMedical DevicesWatertown, US
Sidhant Jena(Executive Officer, Director)Timothy Richards(Executive Officer)Richard Williams(Executive Officer)inAnh Hoang-Lindsay(Executive Officer, Director)Michal Depa(Executive Officer, Director)
BoardEhsan Jabbarzadeh(Director)
Co-investorsHealthXCapitalInnova Capital Partners, LLCPatamar CapitalFirst Avenue VenturesIAG Capital PartnersThe A-Team
Nu-Tek BioSciences manufactures plant- and yeast-based cell culture nutrients and fermentation supplements for pharmaceutical and biotechnology companies.
Advanced ManufacturingBiotechImpact & Social GoodNew MaterialsMinnetonka, US
Thomas Yezzi(Founder & CEO)Kent McCoy(Chief Financial Officer of the Issuer)in
Co-investors1315 Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.